In response to the NIH Program Announcement PAR-13-279, Charles R. Drew University of Medicine and Science (CDU) proposes to continue and expand the success of the Accelerating excellence In Science (AXIS) program. AXIS is the integrated home for clinical and translational research. AXIS houses experienced leadership as well as a myriad of clinical, translational, community-partnered activities, well matched by the education, training, and technology resources and excellent research core services. In the first five years, AXIS has laid the foundation at CDU to establish itself as the central hub of translational research. In the next five years, CDU will continue building on this progress and further develop its focus as the main research infrastructure program that will promote multi- and interdisciplinary collaborations between CDU investigators and community partners targeting health disparities. The vision of the University Research Enterprise is to be a leading player in the national effort to eliminate health disparities, specifically through AXIS in three areas of focus which disproportionally affect Service Planning Area 6: Cancer, Cardiometabolic Disease (CMD), and HIV/AIDS. AXIS proposes three programmatic goals that align with the vision of the University's Research Enterprise: Goal 1: To enhance the infrastructure capacity in translational research in the areas of Cancer, Cardiometabolic, and HIV/AIDS. Although other areas of research at CDU will also be served, the focus will be to create expertise and research success in these three areas.
This aim will also ensure that CDU continues to provide national leadership in reducing health disparities by increasing the quality and quantity of researchers from minority and underserved populations conducting disparities research. Goal 2: To integrate basic, clinical, and community-partnered translational research by fostering collaboration among disciplines, departments and schools at CDU, and collaboration with community leaders and investigators across other research institutions. Goal 3: To facilitate professional development and best practices in mentored clinical and translational research training on minority health and health disparities. To reach these goals, the AXIS Center will include 8 Cores that will offer services, resources, and training for all research conducted at CDU: 1 .Administrative Core, 2.Collaborations and Partnerships, and Community Core, 3.Professional Development and Pilots Core, 4. Evaluation Core, 5.Biomedical Informatics Core, 6.Research Design and Biostatistics Core, 7.Clinical Research Resources and Facilities Core, 8. Technology and Laboratory Core.

Public Health Relevance

Development of a robust infrastructure for clinical and translational research to address high priority disease areas of cancer, cardiometabolic disorders, and HIV/AIDs will significantly impact health disparities among underserved and ethnic/racial minority populations.

Agency
National Institute of Health (NIH)
Institute
National Institute on Minority Health and Health Disparities (NIMHD)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54MD007598-10
Application #
9471232
Study Section
Special Emphasis Panel (ZMD1)
Program Officer
Das, Rina
Project Start
2009-09-28
Project End
2019-04-30
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
10
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Charles R. Drew University of Medicine & Science
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
785877408
City
Los Angeles
State
CA
Country
United States
Zip Code
90059
Hasan, Mohammad Kamrul; Friedman, Theodore C; Sims, Carl et al. (2018) ?7-Nicotinic Acetylcholine Receptor Agonist Ameliorates Nicotine Plus High-Fat Diet-Induced Hepatic Steatosis in Male Mice by Inhibiting Oxidative Stress and Stimulating AMPK Signaling. Endocrinology 159:931-944
Elsaid, Ahmed F; Shaheen, Magda; Ghoneum, Mamdooh (2018) Biobran/MGN-3, an arabinoxylan rice bran, enhances NK cell activity in geriatric subjects: A randomized, double-blind, placebo-controlled clinical trial. Exp Ther Med 15:2313-2320
Sinha-Hikim, Amiya P; Mahata, Sushil K (2018) Editorial: Obesity, Smoking, and Fatty Liver Disease. Front Endocrinol (Lausanne) 9:1
Chung, Seyung S; Dutta, Pranabananda; Austin, David et al. (2018) Combination of resveratrol and 5-flurouracil enhanced anti-telomerase activity and apoptosis by inhibiting STAT3 and Akt signaling pathways in human colorectal cancer cells. Oncotarget 9:32943-32957
Schwartz, Steven; Bazargan-Hejazi, Shahrzad; Pan, Deyu et al. (2018) Association of Psychiatric Diagnostic Conditions with Hospital Care Outcomes of Patients with Orthopedic Injuries. Perm J 22:
Jenders, Robert A; Adlassnig, Klaus-Peter; Fehre, Karsten et al. (2018) Evolution of the Arden Syntax: Key Technical Issues from the Standards Development Organization Perspective. Artif Intell Med 92:10-14
Maxwell, Annette E; Castillo, Laura; Arce, Anthony A et al. (2018) Eating Veggies Is Fun! An Implementation Pilot Study in Partnership With a YMCA in South Los Angeles. Prev Chronic Dis 15:E132
Elshimali, Yahya I; Wu, Yong; Khaddour, Hussein et al. (2018) Optimization Of Cancer Treatment Through Overcoming Drug Resistance. J Cancer Res Oncobiol 1:
Hanuscin, Chris; Zahmatkesh, Golara; Shirazi, Anaheed et al. (2018) Socio-Demographic and Mental Health Profile of Admitted Cases of Self-Inflicted Harm in the US Population. Int J Environ Res Public Health 15:
La, V; Fujikawa, R; Janzen, D M et al. (2017) Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy. NPJ Precis Oncol 1:

Showing the most recent 10 out of 190 publications